Anaemia is common in critical illness, and standard treatment is red blood cell (RBC) transfusion, typically using a restrictive transfusion threshold of 70 g L −1 . However, there are subgroups of patients in whom it is biologically plausible that a higher transfusion threshold may be beneficial, namely, acute sepsis, traumatic brain injury and coexisting cardiovascular disease. In this review article, we will discuss the pathophysiology of anaemia, as well as its prevalence and time course. We will explore the limitations of using haemoglobin concentration as a surrogate for oxygen delivery and the concept of the critical haemoglobin concentration. We will then discuss transfusion thresholds for the general intensive care unit (ICU) population and specific subgroups.
PREVALENCE
The prevalence of anaemia has been increasing in the past decade and is common in both acute and critical illness. This prevalence in hospitalised patients is approximately 40-45% (Spence, 2007; Lin et al., 2013; Stauder & Thein, 2014) . Approximately two-thirds of patients admitted to intensive care unit (ICU) present with Hb concentrations less than 120 g L −1 (Vincent et al., 2002; Corwin et al., 2004 ), 39% present with Hb < 100 g L −1 (Thomas et al., 2010 ) and 25% present with Hb < 90 g L −1 (Walsh et al., 2006a) ; 97% become anaemic by Day 8 and 100% by day 13 (Thomas et al., 2010) . The prevalence of moderate to severe anaemia (Hb concentration < 90 g L −1 ) at some time during ICU stay is approximately 40-50% among most ICU populations (Walsh & Saleh, 2006) .
PATHOPHYSIOLOGY
Acute haemorrhage is an important cause of anaemia, but there are many other causes of anaemia in acute and critical illness. These can be broadly divided into factors affecting red blood cell (RBC) production and factors affecting RBC survival.
Red cell production is suppressed in the presence of functional iron deficiency, reduced erythropoietin production and infection (Vincent et al., 2002) . Anaemia is usually normochromic and normocytic, and the erythropoietic response to anaemia is blunted (Rogiers et al., 1997; Corwin et al., 2002) . This is similar to the anaemia seen in chronic inflammatory disease. Inflammatory cytokines, including tumour necrosis factor alpha, interleukin-1 and interleukin-6, directly inhibit red cell formation (Walsh & Saleh, 2006) . Hepcidin is emerging as a master regulator of iron metabolism, with a key regulatory role via ferroportin. Hepcidin inhibits intestinal absorption of iron (Andrews, 2004) and also inhibits the release of iron from tissue macrophages (Lasocki et al., 2011) . Inflammation also results in the uptake of iron by macrophages, where it is incorporated into ferritin (Weiss & Goodnough, 2005) . This reduces the availability of free iron for erythropoiesis. Total body iron is likely to be normal, but this is difficult to assess as serum ferritin is increased and serum transferrin is decreased as part of the acute phase response (Walsh & Saleh, 2006) . This is a functional iron deficiency where there is an inability to incorporate iron into haemoglobin despite normal iron body stores.
RBC survival may be shortened due to pathogen-and immune reaction-associated haemolysis (Singh et al., 2012) . Haemodilution from volume resuscitation will result in a reduction in Hb concentration, although red cell mass will remain constant in absence of bleeding. Frequent blood sampling alone may amount to 40-70 mL per patient per day, accounting for 30% of required blood transfusions (Hayden et al., 2012) , and further losses may be due to occult gastrointestinal bleeding and haemolysis. 33% had Hb < 100 g L −1 , and 11.3% had Hb < 90 g L −1 . The strongest predictor of Hb < 100 g L −1 at hospital discharge was Hb at the time of ICU discharge, consistent with the relatively slow and 'blunted' recovery from anaemia that occurs in many ICU survivors (Walsh et al., 2006b) . In a separate study, half of the patients who were ventilated >24 h and discharged from ICU with Hb < 100 remained anaemic at 6 months (Bateman et al., 2009) . The anaemia was predominantly normochromic and normocytic and was associated with ongoing inflammation, inappropriate erythropoietin response and poor marrow red cell production following ICU discharge. Patients had a markedly reduced health-related quality of life (HRQoL) at 3 and 6 months compared to the normal population. Compared with non-selected ICU patients (including both anaemic and non-anaemic patients), the mean scores were still reduced, particularly in the physical function category and role physical categories. Beyond the critical care environment, studies have consistently shown an association between anaemia of chronic disease and lower HRQoL (Sabbatini, 2000; Finkelstein et al., 2009) . Fatigue is common in ICU survivors, and many of the physical features of post-ICU syndrome overlap with those of anaemia (Walsh et al., 2015) . However, the causal relationship has not been studied in these patients. Trials of more aggressive management of anaemia in this ICU survivor cohort are required to explore whether reversal of anaemia is associated with improvement in fatigue and other HRQoL measures. Potential interventions include oral and intravenous iron, erythropoietin and RBC transfusion.
MANAGEMENT OF ANAEMIA IN CRITICAL ILLNESS
In the critical care environment, standard management for anaemia remains allogeneic RBC transfusion. Oxygen delivery is determined by cardiac output, Hb concentration and oxygen saturation. Increases in Hb concentration should therefore improve oxygen delivery to the tissues and to the myocardium itself and reduce the compensatory work performed by the heart to increase cardiac output.
Other treatment options for anaemia include oral or intravenous iron and erythropoietin. Free iron has been shown to potentiate bacterial growth (Fishbane, 1999) , which is of particular concern in patients who are already critically ill. The uptake of oral iron is inhibited by hepcidin (increased by the inflammation that typifies critical illness), and once absorbed, little of it is available for erythropoiesis. Furthermore, gastrointestinal side effects such as constipation may limit its tolerance. Intravenous iron has been shown to be effective for increasing haemoglobin concentration outside the ICU but was associated with an increased risk of all-cause infection (Litton et al., 2013) . There have been two recent randomised controlled trials (RCTs) of intravenous iron in critically ill patients (Pieracci et al., 2014; IRONMAN Investigators et al., 2016) . The IRONMAN trial showed that intravenous iron resulted in a higher Hb concentration at hospital discharge but did not significantly reduce the number of RBC units transfused (IRONMAN Investigators et al., 2016) . In a previous RCT, a significant increase in serum ferritin concentration was observed but with no effect on Hb concentration or RBC transfusion requirement (Pieracci et al., 2014) . Erythropoietin is essential for the production of RBCs in the bone marrow and is commonly used for patients with anaemia of chronic disease in cancer and chronic kidney disease. It suppresses apoptosis of erythroid colony-forming units, increasing numbers of normoblasts and then reticulocytes after 3-4 days (Jelkmann & Jelkmann, 2013) . Critically ill patients often display resistance due to inflammatory mediators requiring very high doses of erythropoietin-stimulating agents (ESA), of up to 10 times that used in chronic kidney disease that might only increase Hb concentration by up to 1.5 g L −1 day −1 , compared with 10 g L −1 after transfusion of one RBC unit (Jelkmann & Jelkmann, 2013) . This severely limits the clinical effectiveness of ESAs during critical illness because anaemia occurs acutely and progresses rapidly. Furthermore, in critically ill patients, no significant effect on overall mortality, duration of mechanical ventilation or ICU length of stay has been shown, and there are concerns regarding excess thrombotic events (Zarychanski et al., 2007) .
MEASUREMENT OF OXYGEN DELIVERY
We have no accurate way to measure oxygen delivery. At present, arterial oxygen saturation and PaO 2 remain the principal clinical measures of arterial hypoxaemia. Mixed venous oxygen tension approximates to mean tissue oxygen tension and is useful to detect global decreases in tissue perfusion. However, normal mixed venous oxygen tension does not rule out regional inadequate oxygen delivery, and in fact, both low and elevated measurements are associated with a poor outcome in septic patients (De Backer & Durand, 2014 ). Blood lactate is frequently used in combination with these measurements as a surrogate measure of tissue hypoxia: inadequate cellular oxygenation results in anaerobic metabolism and production of lactic acid. However, lactate has a poor sensitivity and specificity to detect microcirculatory alterations (De Backer et al., 2013) .
Oxygen consumption is a potential surrogate measure as this falls when delivery can no longer meet metabolic demand. This critical value of oxygen delivery was estimated to be 8.2 mL −1 min −1 kg −1 (Shibutani et al., 1983) , where tissue hypoxia is suggested if oxygen consumption fell below this value. Although potentially possible in a controlled research setting, there are too many uncontrolled factors that also impact oxygen consumption in the clinical setting to be able to detect the fall due to inadequate delivery. In addition, accurate measurement is difficult.
Gastric tonometry measures the partial pressure of CO 2 in the stomach. When the perfusion of gastric mucosa is reduced, CO 2 accumulates, and this can be used in combination with systemic bicarbonate concentrations to evaluate the adequacy of gastrointestinal mucosal perfusion (Deschamps et al., 2016) . Trials have used this to guide inotropic/vasopressor therapy and RBC transfusion but have not found significant improvement in mortality outcomes . The methodology of gastric tonometry has been questioned as the systemic bicarbonate concentration may not reflect the concentration in ischaemic mucosa, and as a result, few institutions use gastric tonometry in clinical practice.
Near-infrared spectroscopy (NIRS) uses near-infrared light to compare the ratio of oxygenated to deoxygenated Hb, resulting in an indirect measure of tissue oxygenation (StO 2 ). It has been mainly used in cardiac surgery (Edmonds & Jr., 2006) and neonatal (Plomgaard et al., 2016) and paediatric intensive care, and there is now increased interest in exploring its use in septic shock and neurocritical care (Messerer et al., 2012) . There is considerable intra-and inter-patient variability in the estimation of global oxygenation using NIRS. StO 2 values are mostly influenced by venous HbO 2 saturation, and this proportion varies between underlying conditions -in haemorrhage, e.g. the venous component is significantly reduced. NIRS is unable to detect perfusion heterogeneity, so the interpretation of StO 2 is difficult as it does not represent capillary or mixed venous saturation. There is heterogeneity among studies assessing NIRS in the ICU . At present, NIRS is not used routinely in adult general ICUs.
In summary, currently available technologies for assessing oxygen delivery and/or tissue oxygenation lack sufficient precision and discriminant value to guide blood transfusions in routine clinical practice.
CRITICAL HAEMOGLOBIN CONCENTRATION
The critical haemoglobin concentration may be defined as the concentration at which compensatory mechanisms are exhausted, and further reductions in Hb will lead to a decrease in oxygen delivery and, subsequently, oxygen consumption (McLellan et al., 2003) . Animal models have found this Hb to be around 40 g L −1 (Rasanen, 1992; Van der Linden et al., 1998) , although this depends on the metabolic activity and oxygen extraction capabilities of the tissues. In conscious healthy resting humans undergoing acute isovolumetric reduction of Hb concentration to 50 g L −1 , no evidence of inadequate oxygen delivery (using oxygen consumption and plasma lactate concentrations) was observed (Weiskopf et al., 1998) . Significant ST changes occurred in only two patients (one due to a change in position, the other was heart rate-dependent), and both resolved without sequelae (Weiskopf et al., 1998) . In a subsequent re-analysis of these data, it was suggested that the mean Hb concentration associated with anaemia-induced mortality in humans was around 25 g L −1 and that the presence of cardiovascular disease increased that value (Weiskopf, 2010) .
Symptoms of anaemia, such as breathlessness, fatigue and angina, are related to the speed of onset of the anaemia. Patients with chronic normovolaemic anaemia, without cardiovascular comorbidity, may develop symptoms only when their haemoglobin concentration falls as low as 50 g L −1 (Hebert et al., 1997; Toy et al., 2000) . An analysis of Jehovah's Witness patients concluded that very few deaths due to anaemia occurred in patients with Hb > 50 g L −1 (Viele & Weiskopf, 1994) . In a study, again of Jehovah's witnesses, it was reported that for every 10 g L −1 drop in postoperative haemoglobin below 80 g L −1 , the odds of death increased 2.5 times, and the odds increased 2.1 times for a composite outcome of 30-day mortality or morbidity (serious cardiac events, bacteraemia, pneumonia or deep wound infection) (Carson et al., 2002) .
Hb concentration is measured because it is easy to quantify and because it is responsible for a significant proportion of oxygen delivery. However, a simple concentration does not take into account the compensatory mechanisms mentioned above that occur in anaemia and provides only indirect information concerning global or organ-specific oxygen delivery. The critical Hb concentration will be different for each patient and for different organs, and as we do not have the technology to reliably detect cellular hypoxia, we transfuse RBCs in order to prevent its consequences.
RBC TRANSFUSION

Potential risks of transfusion
Anaemia is generally well tolerated by many hospital patients, and therefore, the benefits of RBC transfusion need to be weighed against the potential risks. The risk of transfusion-transmission infections, such as HIV, hepatitis B and hepatitis C, has reduced significantly over the past few decades and is now very low [USA, risk of HIV per unit of red blood cells 1:1 467 000 (Zou et al., 2010) ; hepatitis C 1:1 149 000 (Zou et al., 2010) ; hepatitis B 1:282 000 to 1:357 000 (Zou et al., 2009) ]. Other general risks include transfusion reactions, transfusion-related acute lung injury (TRALI) and transfusion-associated circulatory overload (TACO) (Toy et al., 2012; Serious Hazards of Transfusion Steering Group, 2013) . The Serious Hazards Of Transfusion (SHOT) report in 2015 reported a risk of mortality of 1.01 per 100 000 components issued [total deaths n = 26, including haemolysis (n = 5), TACO (n = 7), delayed transfusion (n = 6)] and risk of major morbidity of 6.44 per 100 000 (TACO: n = 34, Delayed transfusion: n = 5, Acute transfusion reactions: n = 86) (Bolton-Maggs et al., 2016) .
RBC transfusion has been associated with immune modulation (TRIM). Potential mechanisms include suppression of cytotoxic cell and monocyte activity, release of immunosuppressive prostaglandins, inhibition of interleukin-2 production and increase in suppressor T-cell activity (Cata et al., 2013) . Several studies have found an association between perioperative RBC transfusion and tumour recurrence (Amato & Pescatori, 2006) . However, most perioperative studies have been observational, and it is possible that the number of units transfused is due to the complexity of the surgery and tumour size and invasiveness. The increased mortality seen in patients with large transfusions thus reflects the later stage of the tumour rather than an effect of transfusion, a form of confounding by indication. Immunosuppression has also raised concerns about potential infection, and meta-analyses have found that transfusion was associated with a significantly increased risk of postoperative infection, although the magnitude of this effect is uncertain (Hill et al., 2003; Rohde et al., 2014; Teng et al., 2015) .
It may also be that although the allogeneic red cells increase the oxygen content of the blood, the effects of storage on the red cells (the "storage lesion") render them significantly less effective and potentially harmful. The concentration of 2,3-DPG reduces rapidly, increasing the affinity of the red cells for oxygen and thus potentially reducing offloading of oxygen at the tissues (Klein et al., 2007) . However, 2,3-DPG is regenerated in vivo, returning to near-normal concentrations within a day of transfusion, and the clinical impact of this has not been proven. There is loss of production and increased consumption of red cell nitric oxide. Concentrations of adenosine triphosphate fall, resulting in morphological changes and decline in membrane lipid content and cell rigidity. The stiffened cells undergo haemolysis at a higher rate, leaching out free Hb and cytokines into the circulation, which then cause inflammatory and immunomodulatory responses and local vasoconstriction (Kim-Shapiro et al., 2011; Carson et al., 2016) . However, transfusion of fresh red cells, as compared with standard-issue red cells, has not improved survival among critically ill adults (Lacroix et al., 2015; Heddle et al., 2016; Remy et al., 2016; Cooper et al., 2017) . RBC transfusion is expensive; each unit costs around £120 in the UK (Campbell et al., 2015) . This does not take into account the costs of acquiring the blood or its safe administration, which may triple the costs (Shander et al., 2010) .
Transfusion thresholds
Haemoglobin concentration is the parameter most commonly used to make decisions regarding RBC transfusion. However, there is uncertainty regarding the optimal transfusion threshold where benefits of additional oxygen-carrying capacity outweigh the risks of transfusion. Historically, patients were transfused if Hb concentrations fell below 100 g L −1 (or haematocrit ≤30%) (Adams & Js, 1942) . The landmark Transfusion Requirements in Critical Care (TRICC) trial, published in 1999, showed that using a restrictive transfusion strategy (threshold Hb ≤70 g L −1 , target Hb ≤70-90 g L −1 ) in critically ill patients did not increase 30-day mortality when compared with a liberal transfusion strategy (threshold Hb 100 g L −1 , target Hb 100-120 g L −1 ) (Hebert et al., 1999) . Moreover, the study showed that survival was significantly better in the restrictive arm for subgroups of patients with APACHE II score ≤ 20 (i.e. less critically unwell) and age < 55 years. Recent meta-analyses of randomised controlled trials have also found that a restrictive transfusion approach is as safe or even superior to a liberal transfusion approach (Holst et al., 2015; Carson et al., 2016) , and this is reflected in the majority of guidelines that now recommend a restrictive threshold for haemodynamically stable patients without major comorbidity (American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies, 2006; Carson et al., 2012; Retter et al., 2013; Excellence, 2015; Ireland, 2016) .
However, there are limitations to these guidelines. Three trials account for the majority of the patients in the meta-analyses [TRICC (Hebert et al., 1999) , FOCUS (Carson et al., 2011) and TRISS (Holst et al., 2014) ] and, therefore, have a greater influence over the final meta-analyses. TRICC and TRISS both used a restrictive transfusion threshold of 70 g L −1 , whereas FOCUS used a higher restrictive threshold of 80 g L −1 . Patients with comorbidity are less likely to be recruited into trials (such as patients with cardiovascular disease) or may be actively excluded (such as patients with traumatic brain injury). These issues create uncertainty about the generalisability of findings to all patient groups.
There is also the risk of practice misalignment in fixed intervention trials, where the overall effect can mask potentially divergent effects in subgroups. This was seen in an analysis of the TRICC trial, where patients without ischaemic heart disease had a lower mortality rate when randomised to the restrictive arm, but this masked the higher mortality rate seen in patients with IHD in the restrictive arm (Deans et al., 2007) .
There have been three blood transfusion threshold trials in the past 3 years in more homogeneous populations that have shown worse outcomes in patients randomised to restrictive transfusion thresholds. The TITRe2 cardiac surgery trial found more deaths in the restrictive arm (4.2% vs. 2.6%, P = 0.045) (Murphy et al., 2015) . A higher morbidity and mortality in patients randomised to a restrictive threshold (35.6% vs. 19.6%, P = 0.012) was observed in a recent cancer surgery trial (de Almeida et al., 2015) . Finally, a higher 30-day mortality in the restrictive arm (HR 2.4, 95% CI 1.10-5.20) was reported in elderly patients undergoing hip fracture surgery (Gregersen et al., 2015) . A recent meta-analysis of blood transfusion threshold trials in the perioperative setting also concluded that a more liberal transfusion threshold may be beneficial for perioperative patients (OR 0.81, 95% CI 0.66-1.00) (Fominskiy et al., 2015) .
These conflicting data raise concerns that restrictive transfusion thresholds, especially those close to 70 g L −1 , may not be the safest approach for all patient groups. A default haemoglobin transfusion threshold of 70 g L −1 is likely to be safe for young, less sick patients with no significant comorbidity. However, there are several groups of critically ill patients in whom it is biologically plausible that a higher blood transfusion threshold may be beneficial: patients with acute sepsis, patients with traumatic brain injury and patients with coexisting cardiovascular disease.
Patients with sepsis
Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection (Singer et al., 2016) . Septic shock is sepsis where profound circulatory, cellular and metabolic abnormalities are associated with a greater risk of mortality than with sepsis alone (vasopressor-requiring hypotension and elevated lactate levels). These patients have high mortality rates, with hospital mortality greater than 40%, and patients who survive often have long-term physical, psychological and cognitive disabilities (Iwashyna et al., 2010) .
In the presence of significant organ hypoperfusion, it follows that increasing oxygen delivery by increasing Hb concentration may improve organ dysfunction and subsequent outcomes. The Surviving Sepsis Campaign 2016 recommends that "RBC transfusion occur only when hemoglobin concentration decreases to <7.0 g dL −1 in adults in the absence of extenuating circumstances, such as myocardial ischemia, severe hypoxemia, or acute hemorrhage (strong recommendation, high quality of evidence)" (Rhodes et al., 2017) .
In the Rivers' Early Goal Directed Therapy (EGDT) trial (Rivers et al., 2001) , RBC transfusion to >100 g L −1 was included but only if the mixed venous oxygen saturation was <70% -i.e. there was evidence of inadequate global oxygen delivery and/or high oxygen extraction by tissues. In total, 65% of patients randomised to EGDT received RBC transfusion, compared to only 19% of patients in the usual care arm. Patients in the EGDT arm had significantly better outcomes than patients who received usual care. This trial led to widespread use of more liberal transfusion in patients with early sepsis and evidence of tissue hypoxia and/or inadequate oxygen delivery. More recently, however, three large international multicentre trials [PROMISE (Mouncey et al., 2015) , ARISE (ARISE Investigators et al., 2014) and PROCESS (Pro et al., 2014) ] have shown no benefit to EGDT. There are a number of potential reasons for the discrepancy between these large multicentre trials, and the original single centre 'Rivers trial'. Ten years after this publication, usual care is now considerably different. Patients in ARISE were less critically unwell in the first 24 h of ICU admission and received antibiotics much earlier. Patients in both the usual care arm and the EGDT arm received considerably less fluid and had lower lactate concentrations by 6 h. As a result of these more normal parameters, the percentage of patients receiving RBCs was far lower (ARISE usual care 7%, EGDT 14%). These data reflect a far lower prevalence of inadequate oxygen delivery following initial resuscitation with contemporary sepsis management, such that algorithm-triggered blood transfusions occur infrequently.
The Transfusion Requirements In Septic Shock (TRISS) trial was not an early sepsis intervention trial (the mean time to recruitment was 21 h post-ICU admission) and was not guided by an algorithm based on correction of inadequate oxygen delivery. They recruited a large cohort of sick patients and found that there was no significant overall difference in 90-day mortality between a restrictive transfusion threshold of 70 g L −1 and a liberal transfusion threshold of 90 g L −1 .
Patients with traumatic brain injury
Traumatic brain injury (TBI) accounts for approximately 162 500 hospital admission in the UK each year. In severe TBI, the mortality is high, with hospital mortality approximately 30-50%, and a third of survivors are left with severe neurological sequelae, including persistent vegetative state (Turgeon et al., 2011) . The brain is vulnerable to hypoxia as it has no anaerobic pathway that can compensate in suboptimal oxygenation states. Cerebral blood flow is directly affected by cerebral perfusion pressure and inversely by cerebrovascular resistance. There are complex autoregulation mechanisms based on metabolic, pressure, chemical and neural changes, which ensure appropriate oxygen delivery within a certain range of non-optimal physiological conditions. The blood-brain barrier keeps the brain protected from many influences of the systemic blood circulation. Injuries associated with TBI, such as cerebral contusions, haemorrhage and oedema, exacerbate the insult with loss of cerebral autoregulation and loss of integrity of the blood-brain barrier. Anaemia may decrease oxygen delivery to an already fragile brain, increasing the risk of secondary permanent insults.
There is an absence of high-quality evidence for transfusion thresholds in TBI. Two observational studies found that RBC transfusion was associated with improved brain tissue oxygen measurements (Smith et al., 2005; Zygun et al., 2009) . However, there was no improvement seen in cerebral metabolism when they used cerebral microdialysis in these patients to measure markers of cerebral metabolism. A systematic review of comparative studies found only six studies of transfusion thresholds in TBI, half of which had a high risk of bias (Desjardins et al., 2012) . Overall, there was no evidence to support either a liberal or restrictive transfusion threshold. There is currently no consensus on the optimal transfusion threshold (Desjardins et al., 2012) , and there is considerable variation in transfusion practice (Boutin et al., 2016) . The HEMOTION (HEMOglobin transfusion threshold in Traumatic brain Injury OptimizatioN) trial (NCT03260478) has recently started recruiting and will seek to answer this question.
Patients with cardiovascular disease
Approximately seven million people in the UK have coexisting cardiovascular disease (CVD) (Foundation, 2015; Townsend et al., 2015) . In 2014, CVD was the second most common cause of death in the UK, accounting for 27% of all deaths, 25% of premature deaths in men and 17% of premature deaths in women. The economic burden of CVD is high: in 2013/2014, there were 1.7 million hospital admissions for CVD; NHS England spent £4.3 billion on treating CVD, and Wales spent more than £430 million, and in 2011/2012, Scotland spent nearly £800 million (Townsend et al., 2015) .
The myocardium has a limited anaerobic capacity and is dependent on a continuous supply of oxygen from the coronary circulation. At rest, the coronary blood flow is approximately 250 mL min −1 , representing 5% of cardiac output. The myocardium extracts 75% of the oxygen, which cannot increase significantly in response to increased oxygen demand (Tune et al., 2004) . This is significantly higher than any other major organ. In order to match the considerable increases in myocardial O 2 consumption during exercise (up to five times resting consumption), there must be substantial increases in coronary blood flow.
Anaemia is associated with worse outcomes in patients with CVD, both in terms of severity of illness and mortality. Anaemia is associated with poor outcome in ischaemic heart disease (Zeidman et al., 2004) , chronic heart failure (Szachniewicz et al., 2003) , rhythm disturbance and mortality and major adverse cardiovascular events in acute coronary syndrome (Sabatine et al., 2005) . This may be due to increased myocardial workload and adverse left ventricular and large artery remodelling. Anaemia is also associated with worse postoperative mortality in patients with CVD (Carson et al., 1996) , suggesting that patients with coexisting CVD are less tolerant of anaemia than patients without CVD. Even in the absence of other major disease, anaemia causes an increase in cardiac output, achieved by an increase in heart rate and stroke volume. In the presence of acute and critical illness, hypotension and tachycardia may reduce blood flow through the coronary arteries, whereas the use of catecholamines increases myocardial O 2 demand. Global O 2 demand is also typically increased. These pathophysiological changes mean the myocardial oxygen supply is reduced in patients with anaemia, and for patients with coexisting, atheroma-related, flow-limiting disease, there is limited ability to compensate.
Guidelines recommend a higher transfusion threshold of 80-100 g L −1 in patients with Acute Coronary Syndrome (Excellence, 2015) based on two pilot RCTs (Cooper et al., 2011; Carson et al., 2013) . There is a trial [Myocardial Ischaemia and Transfusion (MINT) Trial] in progress that aims to recruit 3500 patients with acute coronary syndrome (Carson, 2016) .
However, there is less evidence for patients with coexisting CVD who present with other primary diagnoses. These patients are often under-represented in RCTs. Our systematic review found 11 blood transfusion thresholds trials that included patients with coexisting CVD either as the whole population, as a pre-defined subgroup or as a high proportion of patients (Docherty et al., 2016) . We found no difference in 30-day mortality between restrictive and liberal transfusion thresholds. However, we found that patients with coexisting CVD who were randomised to a restrictive transfusion threshold had an increased risk of new acute coronary syndrome (RR 1.78, 95% CI 1.18-2.70). The restrictive transfusion threshold for most of the included trials was 80 g L −1 compared with a liberal transfusion threshold of 100 g L −1 . These trials do not, therefore, provide high-quality evidence that the widely recommended transfusion threshold of 70 g L −1 is as safe as higher thresholds for preventing acute coronary syndrome (ACS) in patients with CVD.
CONCLUSION
Anaemia is prevalent in acute and critical illness and is of multifactorial aetiology. Once patients become anaemic, this frequently persists beyond hospital discharge. Current guidelines support a restrictive transfusion threshold of 70 g L −1 in young patients with low comorbidity. However, Hb concentration is a crude surrogate for oxygen delivery and does not represent oxygen demand, and there are groups of patients in whom there is biological plausibility that a higher threshold may be beneficial. We should consider each patient individually when deciding when to transfuse, and we would recommend more liberal transfusion thresholds in patients with traumatic brain injury and ACS/chronic CVD until high-quality RCTs are performed in these populations.
What is known about the topic?
• Anaemia is prevalent in acute and critical illness and persists well after hospital discharge.
• Red blood cell (RBC) transfusion is the standard treatment for significant anaemia in critical illness.
• Guidelines recommend a restrictive transfusion threshold of 70 g L −1 .
What is new?
There are subgroups of patients in whom it is biologically plausible that a higher transfusion threshold may be beneficial:
• acute sepsis;
• traumatic brain injury;
• coexisting cardiovascular disease. What are the key questions for future work on the topic?
• Further research should be targeted at precision medicine blood transfusion threshold trials in these populations. 
